1  values of fungal disease (85 ng/mL ATP) and tracheobronchitis (123 ng/mL ATP) had a tendency to be l

2 ally ill patients with ventilator-associated tracheobronchitis, AA decrease VAP and other signs and s

3  Mycoplasma pneumoniae (Mp) infections cause tracheobronchitis and "walking" pneumonia, and are linke

4  included the rates of ventilator-associated tracheobronchitis and acute respiratory distress syndrom

5 ll bacterium without a cell wall that causes tracheobronchitis and atypical pneumonia in humans.

6 nd chronic respiratory infections, including tracheobronchitis and community acquired pneumonia, and

7    Mycoplasma pneumoniae is a major cause of tracheobronchitis and pneumonia in older children and yo

8 less prokaryote Mycoplasma pneumoniae causes tracheobronchitis and primary atypical pneumonia in huma

9 e subglottic stenosis developed pneumococcal tracheobronchitis and subsequently had a localized Herpe

10 atients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations o

11 st 14 days; and 2) had ventilator-associated tracheobronchitis defined as the production of purulent

12  three patients with nosocomial pneumonia or tracheobronchitis due to multiresistant strains of P. ae

13 een the two groups for ventilator-associated tracheobronchitis: eight patients (10%) in the povidone-

14 ed lung weight and severity of pneumonia and tracheobronchitis in infected W-sh mice.

15 eumonia; P = 0.857/0.368 and proven/probable tracheobronchitis; P = 0.226/0.529) up to 12 months afte

16 sociated pneumonia and ventilator-associated tracheobronchitis shows promise, but the delivered dose

17  to the development of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumo

18 for the development of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumo